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Xenograft tumorThe discovery of microRNAs (miRNAs) provided a new avenue for early diagnosis and treatment of
GC. MiR-137 has been reported to be under-expressed and involved in various cell processes. How-
ever, the role of miR-137 in GC is less known. In this study, we show that miR-137 is under-expressed
in GC and functions as a tumor suppressor through targeting Cyclooxygenase-2 (Cox-2), which sub-
sequently suppresses the activation of PI3K/AKT signaling pathway both in vitro and in vivo. More-
over, restored Cox-2 expression partially abolished the tumor suppressive effects of miR-137 in GC
cells, suggesting miR-137 may suppress GC carcinogenesis by targeting Cox-2.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer (GC) is one of the most common cancers world-
wide. Although the incidence of GC has decreased during the past
decades, especially in the Western countries, the whole morbidity
and mortality among the world is still high [1]. The etiology of this
neoplasm is complex, and both genetic and environmental factors
contribute to the complicate scenario, which results in a deﬁciency
of internationally accepted standard chemotherapy regimen [2].
Over the past decades, the survival of advanced GC is less than
40% [3]. Thus, a comprehensive understanding of the biology about
this malignancy is deﬁnitely necessary to the development of novel
therapies.
Current recently, accumulating studies reported the important
role of microRNAs (miRNAs) in the initiation and progression of
GC [4,5]. MicroRNAs (miRNAs) represent a group of endogenous,
small, non-coding RNAs that can modulate protein expression
[6]. By partially complementing with the 30-untranslated region
(30UTR) of speciﬁc messenger RNAs, miRNAs induce various target
genes translational silence or cleavage, and thus, participate in a
variety of cell biological progresses [7]. Among of these miRNAs,
miR-137 is an intriguing member, which locates on chromosome1p22 and has been reported to be under-expressed in many can-
cers, such as breast cancer [8], colorectal cancer [9] and non-small
cell lung cancer [10]. Through targeting different mRNAs, miR-137
modulates various cell processes. In breast cancer, miR-137 could
suppress cell proliferation and migration by targeting estrogen
related receptor a (ERRa) [8]. While in colorectal cancer cells, by
suppressing cell division control protein 42 homolog (Cdc42), ecto-
pic miR-137 expression inhibits cell growth, arrests cell cycle and
represses cell invasion [9]. It was recently shown that miR-137 was
signiﬁcantly down-regulated in GC tissues and the suppression
was concurrently with the severity of pathological changes [11],
suggesting the tumor suppressor role of miR-137 in GC. Although
the under-expression of miR-137 has been demonstrated in GC,
the exact effects and relative mechanisms of miR-137 on GC cells
still have not been completely identiﬁed.
Cyclooxygenase-2 (Cox-2) belongs to the Cyclooxygenase (Cox)
family, consisting of Cox-1, Cox-2 and Cox-3. Cox-1 is knownas a con-
stitutively expressed enzyme in almost all tissues, and its regulation
of prostaglandins (PGs) is physically involved inmultiple physiolog-
ical processes such as the secretion of gastric mucosa, renal blood
ﬂow and platelet aggregation [12]. However, Cox-2 is always
reported to be constitutively overexpressed in some pathological
processes, such as injury, inﬂammation and tumorigenesis [13].
Known as an inducible enzyme that catalyzes conversion of arachi-
donic acid (AA) to PGs in response to various inﬂammatory stimuli,
Cox-2 plays an important role in linking chronic inﬂammation to
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widely explored by a large cohort of studies [15]. In addition, Cox-
2 expression has been identiﬁed in some chronic active gastritis
and intestinal metaplasia tissues, and the expression of Cox-2 in
intestinal metaplasia tissues is more severe than the chronic active
gastritis group, suggesting that Cox-2 might play a key role in the
stepwise process leading to gastric carcinogenesis eventually [16].
Moreover, high content of Cox-2 always predicted a higher risk for
GC-related death [17]. These studies provide a solid foundation for
Cox-2 is positively related with GC carcinogenesis. However, how
cancers regulate Cox-2 and the mechanisms involved are still par-
tially understood. Strikingly, a previous work reported that Cox-2
was a direct target gene ofmiR-137 andmediated inmiR-137-med-
iated tumor suppression of glioblastoma carcinogenesis [18]. Thus,
wehypothesized thatmiR-137 inhibitionmightmediate theoverex-
pression of Cox-2 in GC, apart from the traditional regulative
pathway of Cox-2 secretion.
Several studies have demonstrated that Cox-2 expression was
found to be up-regulated in GC tissues and increased metastatic
potential of human gastric cancer cells [15,17]. However, a possible
role of Cox-2 in mediating tumor suppressive effects of miR-137 in
gastric cancer cells has not been investigated. In this study, we
investigated miR-137 regulation of Cox-2 expression in gastric can-
cer cells and whether the effects of miR-137 on cell proliferation
and invasion are mediated by Cox-2.
2. Materials and methods
2.1. Tissue specimens
107 formalin ﬁxed parafﬁn-embedded specimens of gastric can-
cer tissues were collected from department of Digestive Diseases,
the Second Afﬁliated Hospital of Medical School of Xi’an Jiaotong
University. The matched normal tissues were obtained from the
5 cm distant from the tumor margin, which were further con-
ﬁrmed by pathologists. All patients did not perform any therapy
before recruitment to this research. The use of the tissue samples
for all experiments were obtained with informed consent and
approved by the Second Afﬁliated Hospital of Medical School of
Xi’an Jiaotong University institutional Ethics Committee.
2.2. Cell culture
Human GC cell lines (MGC-803, HGC-27, MKN-45 and SGC-
7901) were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). These cells were maintained in RPMI
1640 medium (PAA, Pasching, Austria), supplemented with 10%
fetal bovine serum (FBS; PAA, Pasching, Austria) and streptomycin
(100 lg/mL), penicillin (100 U/mL). Cultures were incubated in a
humidiﬁed atmosphere of 5% CO2 at 37 C.
2.3. RNA extraction, reverse transcription and quantitative real-time
PCR
According to the protocol of Recover All Total Nucleic Acid Iso-
lation Kit (Ambion, Austin, TX, USA), total RNA was isolated from
20-lm sections from formalin-ﬁxed, parafﬁn-embedded tissue
blocks. The expression level of GAPDHwas used as an internal con-
trol of mRNAs, and the U6 level was regard as internal control of
miRNAs, respectively. Total RNA was reversely transcribed using
First-Strand cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA)
with speciﬁc primers qualiﬁed with a Taqman probe. Then, quan-
titative real-time PCR was performed to quantify relative expres-
sion of miRNA and mRNA using the Quanti-TectSYBR Green PCR
mixture on an ABI PRISM 7900 Sequence Detection System(Applied Biosystems, Carlsbad, CA, USA). The primers used for
reverse transcriptions and quantitative RT-PCR were summarized
in Supplemental Table 1. The relative expression levels were eval-
uated using the 2DDCt method.
2.4. Luciferase reporter assays and plasmid construction
The experimental details of luciferase reporter assays and plas-
mid construction have been supplied in Supplemental materials.
2.5. Immunoblot analysis
For the Immunoblot assays, cells were harvested in ice-cold
PBS 48 h after transfection and lysed on ice in cold modiﬁed radi-
oimmunoprecipitation buffer supplemented with protease inhibi-
tors. Upon protein concentration was determined by the BCA
Protein Assay Kit (Bio-Rad, CA, USA), equal amounts of protein
were analyzed by SDS–PAGE. Gels were electroblotted onto nitro-
cellulose membranes (Millipore, Wisconsin, USA). After blocked
with 5% non-fat dry milk in Tris-buffered saline containing 0.1%
Tween-20 2 h, membranes were incubated at 4 C over night with
primary antibodies (Cox-2, p-AKT, AKT, caspase-3, MMP2 and
GAPDH, Cell Signaling, Massachusetts, USA). Then, membranes
were incubated with respective second antibodies and detected
by peroxidase-conjugated secondary antibodies using the
enhanced chemiluminescence system (ECL) (Millipore, Wisconsin,
USA).
2.6. Cell transfection and functional assays
The experimental details of cell transfection and functional
assays have been supplied in Supplemental materials.
2.7. Xenograft experiments
For animal xengraft model assays, 3  106 MGC-803 cells were
subcutaneously injected into the posterior ﬂanks of 6 week old
nude mice, four mice per group. When tumors reached 50 mm3,
miR-137 or scramble mimic (100 nmol) was suspended in Lipo-
fectamine 2000 (100 ll). The diluted miRNA was injected into
the tumors directly. The injections were performed every 3 days
for 6 times totally. Tumor diameters were measured after 7 days
from injection and then every 3 days. At 28 days after injection,
mice were killed and tumors were weighted after necropsy. Tumor
volume was calculated as follows: length width2  1/2. The mice
xenograft model assays were performed according to institutional
guidelines.
2.8. Statistical analysis
Data were expressed as the mean ± standard deviation of at
least three independent experiments. Statistical analysis was car-
ried out using the Student’s t-test for comparisons of two groups,
unless otherwise indicated (v2 test), and data with three groups
were analyzed using a one-way analysis of variance (ANOVA).
Statistical analysis was carried out using SPSS 15.0 software.
P-values < 0.05 were considered signiﬁcant.
3. Results
3.1. miR-137 was under-expressed in GC tissues and cell lines
In an attempt to explore the expression and signiﬁcance of miR-
137 in GC carcinogenesis, we detected the expression of miR-137
in 107 pairs of GC tissues using TaqMan quantitative RT-PCR
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of the GC tissues exhibited under-expression of miR-137 (68%, 73
of 107, Fig. 1A). Moreover, statistical analysis identiﬁed the
under-expression of miR-137 in GC tissues compared with normal
tissues (Fig. 1B). To identify whether this under-expression only
exit in GC tissues, we explored the expression of miR-137 in four
GC cell lines (MGC-803, HGC-27, MKN-45 and SGC-7901) com-
pared with ﬁve randomly chosen specimens whose miR-137 level
were signiﬁcant low. The expression of miR-137 was universally
decreased in these four GC cell lines (Fig. 1C). Finally, MGC-803
and HGC-27 cells were picked out for further experiments, which
were poorly differentiated and undifferentiated, respectively.
These results suggested the under-expression of miR-137 might
be a frequent event in human GC.
3.2. miR-137 functions as a tumor suppressor in GC cells
As miR-137 expression signiﬁcantly decreases in GC, we sought
to compensate for its loss through exogenous transfection with
miR-137 mimic into MGC-803 and HGC-27 cells. Upon transfec-
tion, the intracellular levels of miR-137 were about 550-fold and
900-foud higher in MGC-803 and HGC-27, respectively (Fig. 2A).
Ectopic miR-137 expression led to signiﬁcant decrease in cell pro-
liferation as well as G1 population, and induced apoptosis in both
GC cells (Fig. 2B–D). Moreover, we sought to evaluate the effects of
miR-137 on cell migration and invasion using Transwell assays. As
expected, miR-137 can efﬁciently impair the migratory and inva-
sive capacity of GC cells (Fig 3A and B). Taken together, the data
mentioned above suggest that miR-137 functions as a tumor sup-
pressor in GC cells.Fig. 1. Expression levels of miR-137 in GC specimens and cell lines. (A) The expression o
TaqMan quantitative RT-PCR. Data are shown as log10 of relative ratio change of GC tissu
levels in GC tissues and compared normal tissues; (C) Using quantitative RT-PCR analys
SGC-7901) was analyzed relative to normal gastric tissues. The expression of miR-137 w3.3. miR-137 directly targets Cox-2 in GC cells
To explore the mechanisms involved in miR-137-mediated
tumor suppression, putative targets of miR-137 were searched
using prediction program, miRanda algorithm. Among common
predicted targets of miR-137, Cox-2 was selected out as the effect
of Cox-2 on GC has been widely explored. According to the predic-
tion program guidance, a putative binding site of miR-137 in the
30UTR of Cox-2 gene (896–914 bp) has been reported. To determine
whether the putative binding site perform function, luciferase
reporter assays were performed. As expected, signiﬁcant suppres-
sion of luciferase activity were observed in both GC cell lines co-
transfected with construct containing the 30UTR of miR-137 puta-
tive binding site and miR-137mimic (Fig. 4A), suggesting that miR-
137 suppressed the transcription activity of Cox-2 gene by target-
ing the 30UTR of Cox-2 mRNA independently. Identical to the lucif-
erase reporter assays, we observed the decreased expression of
mRNA and protein of Cox-2 upon transfection with miR-137 mimic
(Fig 4B and C).
Strikingly, in addition to traditionally mediating PG synthesis,
Cox-2-mediated protein kinase B (PKB or AKT) activation was
reported to be involved in multiple tumor processes [19]. There-
fore, we determined the effects of miR-137/Cox-2 interaction on
the activation of phosphatidylinositol 3-kinase/protein kinase B
(PI3K/AKT) signaling pathway. Ectopic expression of miR-137 sup-
pressed the expression of p-AKT and its downstream genes-MMP-2
and caspase-3, while, the expression of total AKT was not inﬂu-
enced (Fig 4C). Collectively, these ﬁndings suggest that miR-137
regulates the expression of Cox-2 post-transcriptionally, which
subsequently suppresses the PI3K/AKT signaling pathway in GC
cells. Moreover, the expression of cox-2 has been identiﬁed to bef miR-137 in 107 pairs of GC tissues and compared normal tissues was detected by
es relative to normal tissues; (B) Statistical analysis of relative miR-137 expression
is, the expression of miR-137 in four GC cell lines (MGC-803, HGC-27, MKN-45 and
ere normalized to small nuclear RNA U6. ⁄⁄P < 0.01.
Fig. 2. MiR-137 suppresses GC cell proliferation. (A) RT-PCR was performed to detect the expression of miR-137 in GC cell lines (MGC-803 and HGC-27) after treatment with
mimics (normalized to U6); (B) CCK-8 was performed to analyze the effect of miR-137 on cell proliferation of MGC-803 and HGC-27 cells; (C, D) The inﬂuences of miR-137 on
cell apoptosis and cell cycle progression were analyzed using ﬂuorescence-activated cell sorting (FACS); ⁄P < 0.05; ⁄⁄P < 0.01.
Fig. 3. MiR-137 inhibits cell migration and invasion. (A, B) The effects of miR-137 on cell migration and invasion were detected using transwell chamber assays. Panel A
showed the results on migration; Panel B showed the results on invasion. The chambers have been coated with Matrigel, which functions as the extracellular cell matrix. MiR-
137 inhibited cells invasion through the membrane. ⁄P < 0.05; ⁄⁄P < 0.01.
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Fig. 4. MiR-137 targets Cox-2 gene in gastric cancer (GC) cells. (A) Relative luciferase activity of the indicated Cox-2 reporter construct in MGC-803 cells, co-transfected with
miR-137 mimic or scramble mimic, is shown; (B) Quantitative RT-PCR assays were performed to detect the expression of Cox-2 upon transfection with miR-137 mimic or
scramble mimic (normalized to GAPDH); (C) Western blot analysis showed the expression levels of Cox-2, p-AKT, AKT, MMP2 and caspase-3 proteins in GC cells treated with
miR-137 mimic. (D) Quantitative RT-PCR assays were performed to detect the expression of Cox-2 in GC tissues (normalized to GAPDH); (E) Inverse correlation between Cox-2
mRNA level and mniR-137 expression in 107 GC samples. ⁄⁄P < 0.01.
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related with the expression of miR-137 (Fig 4E), which further sug-
gested the target role of cox-2 in GC.
3.4. Cox-2 is involved in miR-137-mediated tumor suppression
To further explore whether miR-137-mediated growth inhibi-
tion in GC cells via the direct targeting of Cox-2, we adopted a
‘‘rescue’’ methodology. We generated a new construct containing
the full ORF of Cox-2 gene (pcDNA3.1_Cox-2). As expected, the
expression of Cox-2 was rescued when pcDNA3.1_Cox-2 was trans-
fected into MGC-803 and HGC-27 cells that had been treated with
miR-137 mimic before (Fig. 5A). In agreement with the restored
expression of Cox-2 protein, increased cell proliferation (Fig. 5B),
accompanied with the inhibition of miR-137-mediated-suppres-
sion of cell invasion (Fig. 5C) were observed upon transfection with
pcDNA3.1_Cox-2. These data established the participation of Cox-2
in miR-137 pathway, i.e. the tumor suppressor role of miR-137 in
GC might be typically a consequence of decreased Cox-2
expression.
3.5. miR-137 suppresses tumor growth of GC cells in vivo
Our above ﬁndings strongly suggest the potential therapeutic
target of miR-137 in GC. Finally, we explored the effects ofmiR-137 on gastric tumor growth in vivo. MiR-137 signiﬁcantly
inhibited tumor growth of MGC-803 cells xengrafted mice relative
to the scramblemimic injectedmice (Fig. 6A and B). Consistentwith
the tumor volume, the average tumor weight was also signiﬁcantly
reduced (Fig. 6C). Based on these observations, we speculate that
overexpression of miR-137 in tumor tissues upon local injection
might result in the suppression of tumor growth. To address this,
wemeasured the expression of miR-137 and Cox-2 in the harvested
tumor tissues. Consistent with our in vitro results, the expression of
miR-137was signiﬁcantly increased (Fig. 6D), and the expression of
Cox-2 and p-AKT were decreased in mice treated with miR-137
(Fig. 6E). Moreover, treatment with miR-137 upregulated the
expression of caspase-3 in mice, which means miR-137 promoted
tumor apoptosis of GC in vivo. Thus, introduction of miR-137mimic
may suppress GC carcinogenesis through targeting Cox-2mediated
activation of PI3K/AKT signaling pathway.
4. Discussion
In this paper, we provide important evidence in support of miR-
137 functioning as a tumor suppressor through targeting Cox-2 in
GC, which subsequently suppresses PI3K/AKT signaling pathway.
Recently, miRNAs have been reported to be closely correlated with
the initiation and maintenance of human diseases. Considered to
be important components of gene regulation, miRNAs play a key
Fig. 5. MiR-137 suppresses tumor progression through targeting Cox-2 in gastric cancer (GC). (A) Upon transfection with Cox-2 construct, we rescued the expression of Cox-2
in both GC cell lines; (B) CCK-8 assays were used to detect to explore the effects of miR-137/Cox-2 interaction on cell proliferation; (C) Transwell assays were performed to
detect the effects on cell invasion of MGC-803 and HGC-27 cells treated as described in (B). ⁄P < 0.05; ⁄⁄P < 0.01.
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biomarkers of the diseases [20]. For instance, the expression of
miR-219-2-3p was signiﬁcantly down-regulated in GC tissues
compared with matched adjacent normal tissues, and the low level
was associated with high-grade and last-stage tumors [21]; Rever-
sely, the expression of miR-215 was signiﬁcantly up-regulated in
GC and inhibition of miR-215 expression suppressed GC cell prolif-
eration via G1 phase arrest by targeting restinoblastoma tumor
suppressor gene 1 (RB1) [22]; In addition, several studies provided
the evidence that tumor-associated circulating miRNAs might have
great potential to serve as novel, non-invasive biomarkers for early
detection of GC [23]. These studies provide a solid foundation for
gastric cancer utilization of miRNAs in diagnostic and anticancer
therapy in future.
Currently, Du et al. characterized GC-related methylation of 9
miRNAs CpG islands, among of which the methylation frequency
of miR-137 gradually increased during the gastric carcinogenesis,
and the methylation rate of miR-137 positively correlated with
the depth of invasion, pTNM, lymph metastasis, and vessel embo-
lus of GCs [11]. As DNA methylation can affect large regions of
chromatin regulating the transcription of distant genes, subse-
quently, the expression of miR-137 was validated to be signiﬁ-
cantly decreased in GCs. Consistent with their study, our study
found the expression of miR-137 is signiﬁcantly decreased in 107GC specimens and cell lines compared with adjacent normal tis-
sues, further suggesting the tumor suppressor role of miR-137 in
GC. Although the under-expression of miR-137 in GCs has been
veriﬁed, the comprehensive biological functions and relative
mechanisms have not been identiﬁed yet. To further assess miR-
137 function in connection with tumor cell characteristics, we ana-
lyzed the biological functions of miR-137 on GC cell lines MGC-803
and HGC-27. We restored the expression of miR-137 in both cell
lines. As expected, over-expression of miR-137 markedly inhibited
cell proliferation, arrested cell cycle progression and induced cell
apoptosis of both GC cell lines. These results are consistent with
Chen et al. reports. They found that miR-137 induced apoptosis
and cell cycle G1 arrest in GC cells and this might be related to
the inactivation of Cdc42 [18]. Moreover, in our paper, miR-137-
transfected cells also showed a dramatic decrease in cell migration
and invasion. These results shown here demonstrate that miR-137
could suppress the carcinogenesis of GC in vitro. Additionally,
over-expression of miR-137 ameliorated the progression of GC in
an established experimental xenograft model, which suggests
miR-137 could suppress the carcinogenesis of GC in vivo. Based
on the data mentioned above, it provides the strong evidence that
miR-137 is a tumor suppressor in GC.
Since miRNAs regulate multiple mRNAs, it is important to
explore the putative target genes involved in miR-137-mediated
Fig. 6. MiR-137 inhibits GC growth in vivo. (A) Graphic representing tumor volumes at the end of the experiment for mice treated with miR-137 mimic or scramble mimic.
Four mice per group; (B) Tumor volume averages between scramble and miR-137 mimic treated mice groups at the indicated days during the experiment; (C) Tumor weight
averages between scramble and miR-137 mimic treated mice groups at the end of the experiment (28 days); (D) Quantitative RT-PCR analysis showed the relative expression
of miR-137 in injected tumor tissues (normalized to U6); (E) Representative images of the immunohistochemistry analysis of Cox-2, caspase-3 and p-AKT in tumors from
xenograft mice. Data are presented as means ± SD. Statistical analysis was carried out using ANOVA. ⁄⁄P < 0.01.
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binding site of miR-137 in the 30UTR of Cox-2. Further luciferase
assays, accompanied with mRNA and protein assays validated this
site perform function, i.e. through transfection with miR-137, the
expression of Cox-2 mRNA and protein could be both down-regu-
lated in GC cells. Moreover, to further explore the relationship
between miR-137 and Cox-2, we analyze their expression in xeno-
graft mice treated with miR-137 mimic using RT-PCR and Immu-
nohistochemistry assays, respectively. Their expressions were
inversely related in tumors of xenograft mice. Although Cox-2
has been reported to be involved in miR-137-mediated tumor sup-
pression of glioblastoma cells [24], this is the ﬁrst time to explore
the role of miR-137/Cox-2 interaction in GC cells.
Recently, the mechanisms involved in Cox-2-mediated tumor
progression have been widely explored, especially the interplay
between Cox-2 and PI3K/AKT signaling. PI3K/AKT signaling path-
way mediates important signaling transduction in cell biological
processes [25,26]. Crosstalk between Cox-2 and PI3K/AKT signaling
pathway have been widely reported. Combined with Cox-2 inhibi-
tion, wogonin increased hepatocellular carcinoma cells sensitivity
to chemotherapeutic agents partially through regulation of PI3K/
AKT signaling [27]. To identify the mechanisms involved, dozens
of experiments were performed. A previous work reported that
Cox-2 could positively regulate AKT signaling via suppression of
PTEN activity, which is the upstream of AKT and mediates it phos-
phorylation [19]. While, another recent study showed that prosta-
glandin E2 (PGE2), the production of Cox-2, was also involved in
activation of PI3K/AKT pathway [28]. However, there also existed
an experiment identiﬁed that this function did not perform effects.
They found that Cox-2 stimulated the activity of protein kinase C
(PKC) to enhance the phosphorylation of Jun N-terminal kinases
(JNKs), but not that of AKT family members in estrogen receptor
(ER) positive cells [29]. This difference might due to the different
microenvironments between various cells. Herein, we have identi-
ﬁed that restored miR-137 suppressed the expression of p-AKT and
its downstream genes, MMP2 and caspase-3. However, the expres-
sion of total AKT was not inﬂuenced upon transfection, suggesting
that miR-137 targets Cox-2, which in turn suppresses PI3K/AKT sig-
naling pathway in GC cells. Further xenograft mice assays alsoshowed that miR-137 suppressed the expression of Cox-2 and p-
AKT in vivo. However, more experiments are warranted to explore
the exact mechanisms involved.
Although we did not explore the role of Cox-2 in GC in this
paper, it has been widely identiﬁed by others. Ding et al. inhibited
the expression of Cox-2 by siRNA in GC cell line MKN-45, which led
to a reduced proliferation, induction of apoptosis, connected with
downregulation of Bcl-2 and upregulation of Bax [30]. A similar
study found that Cox-2-siRNA-treated SGC-7901 cells showed the
suppression of cell proliferation, migration and tube formation
[31]. Based on the ﬁndings that inhibition of Cox-2 resulted in a
near complete phenocopy of the effects of miR-137, we speculate
that Cox-2 is a central for the suppressive actions of miR-137 in
GC. As expected, restoring the expression of Cox-2 in both GC cell
lines partially abolished miR-137-mediated tumor suppression.
Taken together, these results identiﬁed that down-regulation of
miR-137 in GC cells may contribute to the increased expression
of Cox-2 and in turn facilitate the gastric carcinogenesis.
Taken together, our results establish a functional link between
miR-137 and Cox-2 expression in gastric cancer, demonstrating
that Cox-2 is directly repressed by miR-137, which subsequently
inhibits PI3K/AKT signaling pathway. Restoring miR-137 function
could represent an alternative approach to reduce therapeutically
Cox-2 expression, thereby attenuating aggressive tumor properties
in vitro and in vivo. Collectively, this ﬁnding not only helps us
understand the molecular mechanism of gastric carcinogenesis,
but also gives us a strong rationale to further investigate miR-
137 as a potential biomarker and therapeutic target for GC.Disclosure statement
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